Distillations | Science History Institute

When Rebekah and Evan Lockard's daughter, Naomi, was diagnosed with a devastating ultra-rare genetic disease, they didn't know where to turn. Then they found Terry Pirovolakis, an IT professional who had made a gene therapy for his son with the same disease. But the process of getting Naomi treated has been an uphill battle, full of financial and logistical obstacles. The Lockard's story flips the question we've been asking all sea...

Gene therapy is based on a simple-sounding, yet deceptively complicated premise: adding or replacing faulty genes to fix medical problems. A compelling idea that came out of breakthroughs in DNA research, the field grew lightning fast. But the death of teenager Jesse Gelsinger after a gene therapy clinical trial left the public and scientists questioning the field's promise. 

Why did researchers push ahead with clinical trials...

Producer Mariel Carr talks to historian of science and former Science History Institute fellow, Luis Campos, about his article "Strains of Andromeda: The Cosmic Potential Hazards of Genetic Engineering." He shares how Michael Crichton's first novel and the subsequent film influenced the conversation and controversy around recombinant DNA research in the 1970s.

Credits

Host: A...

In 1976, Harvard University wanted to build a specialized lab for recombinant DNA research. But first, it had to get permission from the city of Cambridge. The resulting city council hearings drew TV stations and captured the attention of the whole country. At the center of the controversy? A wise-talking mayor, a young outspoken molecular biologist, and an important question: in scientific research, how much say should the public ...

Genetic engineering breakthroughs in the late 1960s and early 1970s came with a lot of promise—and peril too. Fears about what could happen with recombinant DNA experiments put scientists in the middle of a moral dilemma. Did they have a responsibility to consider how  others might use their work? Or was their place simply to be on the lab bench? In this two-part episode, we'll share the story about the first time scientists s...

Genetic engineering breakthroughs in the late 1960s and early 1970s came with a lot of promise—and peril too. Fears about what could happen with recombinant DNA experiments put scientists in the middle of a moral dilemma. Did they have a responsibility to consider how  others might use their work? Or was their place simply to be on the lab bench? In this two-part episode, we'll share the story about the first time scientists s...

Feeding kids a healthy lunch every school day is a feat of science and logistics. Molded into shape by nutrition scientists who wanted to optimize children's health, the school lunch has endured war, economic depression, and even a global pandemic. Some might say it's all the stronger for it. So how did all these crises shape school lunch? And is there any room to give our rectangle pizzas and frozen chicken patties a little grace?

ALS is a fatal neurological disease that kills motor neurons. Even though it was first described more than 150 years ago, there is no cure, and the few drugs available only dampen the symptoms or slow the progression by a few months. In recent years new drugs have emerged. However, there is one problem: the life expectancy is just two to five years after diagnosis. This timeline is incompatible with the FDA drug approval process, w...

For more than 100 years, biologists who suggested that some cancers may be caused by viruses were the pariahs of genetics. However, they persevered and incrementally built their knowledge, leading to the discovery of retroviruses, the development of a test to diagnose HIV, and the creation of the HPV vaccine. Join us as we interview Gregory J. Morgan about his book Cancer Virus Hunters: A History of Tumor Virology.